Neuraxis, Inc. disclosed estimated financial results for its third quarter and the first nine months of 2025, reporting approximately $0.8 million in net sales for the quarter and a 37% increase in net sales for the year-to-date period.
The company expects cash and cash equivalents to be approximately $4.4 million as of September 30, 2025. For the three months ended September 30, 2025, Neuraxis anticipates net sales of approximately $0.8 million, gross profits of about $0.7 million, and an operating loss of approximately $2.1 million. For the nine months ended September 30, 2025, net sales are estimated at $2.6 million, an increase from approximately $1.9 million for the same period in 2024.
Neuraxis stated that these are preliminary, unaudited estimates prepared by management and are subject to change. The company cautioned that undue reliance should not be placed on these estimates, as it finalizes its financial statements.
